FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to medical products used as an ophthalmic agent, containing riboflavin and pharmaceutical aids applied for a cross-linking procedure in corneal ectasias. The agent contains riboflavin mononucleotide, dextran, sodium chloride, tris-(hydroxymethyl)-methylamine, nipagin, trilon and purified distilled water in a certain relation of components.
EFFECT: invention provides prolonged action of the ophthalmic agent, improves its chemical and bacteriological stability in a solution.
1 ex
Title | Year | Author | Number |
---|---|---|---|
OPHTHALMIC CROSS-LINKING AGENT-2 | 2012 |
|
RU2475248C1 |
OPHTHALMIC AGENT FOR TRANSEPITHELIAL ULTRAVIOLET CORNEAL COLLAGEN CROSSLINKING | 2014 |
|
RU2560669C1 |
OPHTHALMOLOGICAL MEANS FOR ULTRAVIOLET CORNEAL CROSSLINKING | 2016 |
|
RU2646452C1 |
HYPOSMOTIC OPHTHALMIC MEANS FOR ULTRAVIOLET CROSSLINKING OF THIN CORNEAS | 2016 |
|
RU2631604C1 |
METHOD OF TREATMENT OF KERATECTASIA BY THE METHOD OF PULSE ACCELERATED ULTRAVIOLET CROSSLINKING OF CORNEA | 2017 |
|
RU2682494C1 |
COMBINED METHOD FOR THE TREATMENT OF CORNEAL DISEASES WITH THE USE OF KERATOPLASTY AND CROSS-LINKING | 2017 |
|
RU2676434C1 |
METHOD OF TREATING EPITHELIAL-ENDOTHELIAL CORNEAL DYSTROPHY | 2019 |
|
RU2703361C1 |
METHOD OF CORNEAL GRAFT PREPARATION FOR LAYER-BY-LAYER KERATOPLASTY | 2019 |
|
RU2723135C1 |
METHOD OF TREATING HERPETIC KERATITIS | 2013 |
|
RU2531426C1 |
METHOD FOR CONDUCTING ULTRAVIOLET CORNEAL CROSS-LINKING USING BIOLENS WITH THIN CORNEA | 2020 |
|
RU2739995C1 |
Authors
Dates
2011-02-27—Published
2009-10-21—Filed